Farmers National Bank reduced its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 6.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,181 shares of the company’s stock after selling 2,282 shares during the period. Merck & accounts for about 1.3% of Farmers National Bank’s investment portfolio, making the stock its 24th largest position. Farmers National Bank’s holdings in Merck & were worth $2,196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Boston Partners lifted its holdings in shares of Merck & by 2.6% during the 1st quarter. Boston Partners now owns 19,935,016 shares of the company’s stock worth $1,266,671,000 after acquiring an additional 500,476 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Merck & by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,821,563 shares of the company’s stock worth $624,064,000 after acquiring an additional 41,748 shares during the period. Bank of Montreal Can lifted its holdings in shares of Merck & by 49.7% during the 1st quarter. Bank of Montreal Can now owns 8,991,093 shares of the company’s stock worth $571,295,000 after acquiring an additional 2,983,319 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Merck & by 23.7% during the 1st quarter. AQR Capital Management LLC now owns 8,146,594 shares of the company’s stock worth $517,635,000 after acquiring an additional 1,561,853 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Merck & by 0.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,937,918 shares of the company’s stock worth $504,375,000 after acquiring an additional 46,053 shares during the period. Institutional investors and hedge funds own 73.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/13/merck-company-inc-mrk-stake-decreased-by-farmers-national-bank.html.

Shares of Merck & Company, Inc. (NYSE MRK) traded down 0.0371% during trading on Wednesday, reaching $65.4357. The company had a trading volume of 2,018,266 shares. The stock has a 50 day moving average price of $63.05 and a 200 day moving average price of $63.70. The firm has a market capitalization of $178.47 billion, a PE ratio of 35.4281 and a beta of 0.81. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80.

Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same period in the prior year, the business posted $0.93 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. On average, equities research analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio is currently 76.11%.

MRK has been the topic of several recent analyst reports. Vetr lowered shares of Merck & from a “strong-buy” rating to a “buy” rating and set a $69.99 price objective on the stock. in a report on Wednesday, May 17th. Credit Suisse Group set a $72.00 price target on shares of Merck & and gave the company a “buy” rating in a report on Tuesday, June 6th. BMO Capital Markets restated a “buy” rating and issued a $74.00 price target on shares of Merck & in a report on Tuesday, June 6th. Zacks Investment Research upgraded shares of Merck & from a “hold” rating to a “buy” rating and set a $73.00 price target on the stock in a report on Friday, May 26th. Finally, Piper Jaffray Companies set a $70.00 price target on shares of Merck & and gave the company a “buy” rating in a report on Saturday, July 29th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. Merck & has a consensus rating of “Hold” and an average price target of $70.00.

Merck & Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.